JN Biosciences LLC

November 21, 2022

A phase 3 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by Arcus Biosciences was initiated for treatment of advanced upper gastrointestinal tract adenocarcinoma (NCT05568095).  The title of the study is "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)."

October 12, 2022

A phase 3 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by Gilead Sciences was initiated for treatment of non-small cell lung cancer (NCT05502237).  The title of the study is "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)."

September 22, 2022

The PCT application entitled "Biofunctional Molecules for Treatment of Immune Disorders" (WO2022/197610) was published.  In this patent application, JN Biosciences' engineered IgG antibodies that (i) block CD80, CD86 and CD122 and (ii) show potent immune suppressive activities are claimed.  Such engineered antibodies, which block CD28-mediated activation of T cells (primary immune responses) and IL-15-mediated activation of memory T cells (secondary immune responses), are expected to be efficacious for treatment of allograft rejection and GVHD.  

June 7, 2022

Dr. Roger Tieu of Dr. Fadi Lakkis lab at Starzl Transplantation Institute, University of Pittsburgh, presented a poster entitled "IL-15 Signaling is Required for the Maintenance of Tissue Resident Memory T Cells in Chronic Allograft Rejection" at the 2022 American Transplant Congress.  JN Biosciences' anti-mouse CD122 antibody ChMBC7, which is a surrogate of an anti-human CD122 antibody HuABC2, was used in this study to reach the conclusion "Disrupting IL-15 signaling through the use of anti-CD122 blocking antibody could serve as a potential approach to the prevention of chronic rejection."

May 17, 2022

A U.S. patent (11332532) was issued for JN Biosciences' anti-PD-L1/GITR bispecific antibody (ActYbody™)  which (i) blocks the interaction between PD-1 and PD-L1 and (ii) activates the GITR-mediated costimulatory pathway to enhance immune responses.  The anti-PD-L1/GITR ActYbody™ is expected to be an effective immunotherapy agent for treatment of cancer and infectious disease.    

Februarly 18, 2022

A phase 3 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by AstraZeneca was initiated for treatment of non-small cell lung cancer (NCT05211895).  The title of the study is "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)."